AbbVie, Inc's Earnings Made Easy

AbbVie, Inc  (NYSE: ABBV  ) reported earnings last week, with revenue up 5% year-over-year to $4.6 billion. Adjusted eps grew to $0.71, up 4% from last year and above management's previous guidance range.

Humira, the current best-selling drug in the world, generated $2.6 billion in sales this past quarter, up 18% in constant currencies. SG&A expenses grew to 29% of sales, driven in part by preparation for the potential launch of its interferon-free all-oral hepatitis C cocktail, which was recently submitted to the FDA for approval. Like Gilead  (NASDAQ: GILD  ) , AbbVie's management didn't include potential hepatitis C sales in revenue guidance for the rest of the year.

The hepatitis C fight is heating up, and in this video, Motley Fool health care analysts David Williamson and Michael Douglass discuss what AbbVie investors should be focusing on for the rest of the year.

6 stock picks poised for incredible growth -- can they beat AbbVie and Gilead?
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2931928, ~/Articles/ArticleHandler.aspx, 8/20/2014 5:36:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement